Fresenius SE & Co KGaA (FRE) PT Set at €46.00 by UBS Group

Fresenius SE & Co KGaA (FRA:FRE) received a €46.00 ($53.49) price target from research analysts at UBS Group in a research note issued to investors on Thursday, Borsen Zeitung reports. The firm presently has a “neutral” rating on the stock. UBS Group’s price target suggests a potential downside of 9.48% from the company’s current price.

FRE has been the topic of a number of other research reports. Jefferies Financial Group set a €53.00 ($61.63) price objective on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research note on Thursday, March 7th. Berenberg Bank set a €70.95 ($82.50) price objective on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Credit Suisse Group set a €45.00 ($52.33) price objective on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research note on Wednesday, January 23rd. HSBC set a €55.00 ($63.95) price objective on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research note on Wednesday, February 13th. Finally, Goldman Sachs Group set a €52.00 ($60.47) price objective on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research note on Monday, February 25th. Ten analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of €59.29 ($68.94).

Fresenius SE & Co KGaA stock opened at €50.82 ($59.09) on Thursday. Fresenius SE & Co KGaA has a 52 week low of €60.16 ($69.95) and a 52 week high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Further Reading: Why do company’s buyback their stock?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.